Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Quint

Cardiovascular Disease San Jose, CA Medical Doctor

NPI 1649348350 CMS profile 210136

173 N Morrison Ave, Suite C, San Jose, CA 95126

Open in the dashboard

General payments

$5,975

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Quint of San Jose, CA is reported in the CMS Open Payments database as having received $5,975 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $569 19
2024 General $809 28
2023 General $1,149 33
2022 General $869 21
2021 General $574 7
2020 General $522 25
2019 General $1,484 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Quint
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Robert Quint were reported at $569. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Robert Quint Cardiovascular Disease median Middle half National median
2019 $1,484 $450 $127–$1,392 $163
2020 $522 $242 $77–$751 $114
2021 $574 $335 $101–$1,037 $132
2022 $869 $395 $121–$1,211 $149
2023 $1,149 $443 $136–$1,283 $160
2024 $809 $450 $136–$1,323 $164
2025 $569 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $587 15 payments
  2. Merck Sharp & Dohme Corporation $537 15 payments
  3. Shockwave Medical, Inc $524 5 payments
  4. Novartis Pharmaceuticals Corporation $491 24 payments
  5. Pfizer Inc. $411 17 payments
  6. Philips Electronics North America Corporation $401 3 payments
  7. Amgen Inc. $355 14 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $335 44 payments
  9. Janssen Pharmaceuticals, Inc $304 15 payments
  10. Amarin Pharma Inc. $288 16 payments
  11. Other $1,743 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,596 161 payments
  2. Education $379 46 payments
Products named General payments · program years 2019–2025
  1. VERQUVO Cardiovascular $608 18 payments
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $524 5 payments
  3. ELIQUIS $411 17 payments
  4. Repatha $306 12 payments
  5. XARELTO $304 15 payments
  6. LEQVIO $289 13 payments
  7. WATCHMAN FLX $230 10 payments
  8. Vascepa $226 13 payments
  9. WATCHMAN $193 3 payments
  10. VERQUVO Cardiovascular $187 4 payments
  11. Other $3,121 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

723

Median for Cardiology: 2,533

Drug cost

$175,082

Median for Cardiology: $485,213

Branded share of claims

34.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 40 $45,390
Xarelto Rivaroxaban Brand 22 $22,623
Jardiance Empagliflozin Brand 17 $21,882
Entresto Sacubitril/Valsartan Brand 16 $19,937
Verquvo Vericiguat Brand 25 $18,210
Farxiga Dapagliflozin Propanediol Brand 15 $10,314
Brilinta Ticagrelor Brand 17 $10,143
Testosterone Generic 11 $9,018
Dofetilide Generic 26 $5,484
Flecainide Acetate Generic 23 $1,569

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$88,929

Of which drugs: $72

Medicare patients

100

Average age 79

Services billed

706

49 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 71%
Diabetes 49%
Atrial fibrillation 44%
Heart failure 41%
Chronic kidney disease 40%
Arthritis 35%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution, 250 cc J7050 Office 12 81 $42

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $118
$118 40 —
NEXLETOL
  • Esperion Therapeutics, Inc. $78
$78 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $70
$70 25 —
NEXLIZET
  • Esperion Therapeutics, Inc. $62
$63 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $58
$58 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record